Staufen1 regulating agents and associated methods

1. A therapeutic composition comprising:

an amount of a Staufen1-regulating agent sufficient to treat a neurological condition by reducing Staufen1 in a target cell by at least 30% when administered in an effective dosing regimen as compared to levels of Staufen1 prior to or without administration of the Staufen1-regulating agent; and

a pharmaceutically acceptable carrier;

wherein the Staufen1-regulating agent comprises a nucleotide sequence that is at least 80% homologous to and having the same number of nucleotides as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, or a combination thereof.

2. The composition of claim 1 , wherein the Staufen1-regulating agent comprises an antisense oligonucleotide (ASO), a small interfering RNA (siRNA), or a combination thereof.

3. The composition of claim 1 , wherein the Staufen1-regulating agent reduces Staufen1 expression, reduces Staufen1 activity, reduces or blocks Staufen1 interaction with mRNAs resulting in altered mRNA expression or abundance, or a combination thereof.

4. The composition of claim 1 , wherein the Staufen1-regulating agent is present in a formulation at a concentration of from about 1 picomolar (pM) to about 100 millimolar (mM).

5. The composition of claim 1 , wherein the Staufen1-regulating agent is present in a formulation at a concentration of from about 0.001 μg/g to about 200 mg/g.

6. The composition of claim 1 , further comprising a delivery vector to facilitate delivery of the Staufen1-regulating agent into a target cell.

7. The composition of claim 6 , wherein the delivery vector is a viral vector.

8. The composition of claim 7 , wherein the viral vector is a member of the group consisting of: a retrovirus, a lentivirus, a cytomegalovirus, an adenovirus, an adeno-associated virus, and combinations thereof.

9. The composition of claim 6 , wherein the delivery vector is a non-viral carrier selected from the group consisting of: an aptamer, an antibodies, an antibody fragment, a polypeptides, N-acetylgalactosamine, a vitamin, a small organic molecules, a polycationic peptide, a polymers, a dendrimer, a lipid, a lysosomal carrier, a liposome, a micelle, a quantum dot, a nanoparticle, and combinations thereof.

10. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is formulated for administration via injection, enteral administration, transdermal administration, transmucosal administration, inhalation, or implantation.

11. The composition of claim 1 , wherein the pharmaceutically acceptable carrier comprises water, a solubilizing agent, a tonicity agent, a pH adjuster, a buffering agent, a preservative, a chelating agent, a bulking agent, a binder, a disintegrant, a filler, a thickener, a dispersant, an emulsifier, an emollient, or combinations thereof.

12. The composition of claim 1 , further comprising a supplementary therapeutic agent.

13. The composition of claim 12 , wherein the supplementary therapeutic agent is a member selected from the group consisting of: a dopaminergic agent, a cholinesterase inhibitor, an antipsychotic agent, an analgesic, an anti-inflammatory agent, an inducer of autophagy, and combinations thereof.